Therapeutic Response

PD-L1 >= 50%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Tecentriq (atezolizumab) [product monograph]. HC. Health Canada approved atezolizumab as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained >= 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering >= 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.